#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	21152	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2637	972.8	0	.	n	.	0	A69G	SNP	69	69	A	555	555	G	1304	G,A,C	974,327,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	21152	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2637	972.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1936	1936	T	1400	T,G,C,A	1391,4,2,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	21152	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2637	972.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1670	1670	C	1340	C,T,G	1338,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	21152	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2637	972.8	0	HET	.	.	.	T454TG	.	454	454	T	940	940	T	1379	TG,T	997,353	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35790	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4199	1064.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	2044	2044	A	1399	A,G	1397,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35790	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4199	1064.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2678	2678	C	1260	C,G	1258,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35790	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4199	1064.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2752	2752	A	1159	A	1159	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	35790	23S	2890	2890	99.93	23S.l6.c30.ctg.1	4199	1064.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3304	3304	C	1230	C,T,G,A	1226,1,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	3208	folP	852	852	99.88	folP.l15.c4.ctg.1	2114	189.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1101	1103	AAA	286;285;285	A;A;A	286;285;285	.	.
folP.WHO_X_01360c	folP.WHO_X_01360c	1	1	539	3208	folP	852	852	99.88	folP.l15.c4.ctg.1	2114	189.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1332	1334	AGC	315;320;320	A;G;C	315;320;320	folP.WHO_X_01360c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7196	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3941	228.0	1	SNP	p	S91F	0	.	.	271	273	TCC	873	875	TCC	273;273;272	T,G;C;C	271,2;273;272	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7196	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3941	228.0	1	SNP	p	D95G	0	.	.	283	285	GAC	885	887	GAC	284;286;289	G;A;C	284;286;289	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	7196	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3941	228.0	1	SNP	p	D95N	0	.	.	283	285	GAC	885	887	GAC	284;286;289	G;A;C	284;286;289	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	3000	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1945	192.6	1	SNP	p	G45D	0	.	.	133	135	GGC	840	842	GGC	332;334;333	G,T;G;C,G	331,1;334;332,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1578	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1440	136.3	0	.	n	.	0	A197.	DEL	197	197	A	771	771	A	315	A	315	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6960	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3510	247.5	1	SNP	p	D86N	0	.	.	256	258	GAC	825	827	GAC	287;291;294	G;A;C	287;291;294	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6960	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3510	247.5	1	SNP	p	S87I	0	.	.	259	261	AGT	828	830	AGT	295;293;290	A,T,C;G;T,G,A	293,1,1;293;288,1,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6960	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3510	247.5	1	SNP	p	S87R	0	.	.	259	261	AGT	828	830	AGT	295;293;290	A,T,C;G;T,G,A	293,1,1;293;288,1,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6960	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3510	247.5	1	SNP	p	S87W	0	.	.	259	261	AGT	828	830	AGT	295;293;290	A,T,C;G;T,G,A	293,1,1;293;288,1,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	6960	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3510	247.5	1	SNP	p	S88P	0	.	.	262	264	TCC	831	833	TCC	292;292;289	T,A;C;C	291,1;292;289	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	6086	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3278	231.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1861	1863	GGC	331;335;326	G;G,T;C	331;334,1;326	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1501	1503	GCA	342;341;343	G,T;C,A;A,C	341,1;340,1;342,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1504	1506	ATC	345;343;342	A;T,G,C;C,T,A	345;341,1,1;340,1,1	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1516	1518	GTG	330;327;327	G,A;T,A,G;G	329,1;325,1,1;327	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1516	1518	GTG	330;327;327	G,A;T,A,G;G	329,1;325,1,1;327	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2020	2022	ACC	302;301;300	A;C;C,G	302;301;299,1	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2074	2076	GCG	288;287;286	G,T;C;G	287,1;287;286	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2074	2076	GCG	288;287;286	G,T;C;G	287,1;287;286	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2197	2199	GGC	310;308;305	G,T;G,A;C,G,A	309,1;307,1;303,1,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2206	2208	GGC	323;321;322	G,T;G,C;C	322,1;320,1;322	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	5704	penA	1749	1749	100.0	penA.l15.c17.ctg.1	2916	244.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2224	2226	CTG	331;331;334	C;T;G,T	331;330;333,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	8180	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3745	272.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1980	1982	CCG	317;321;321	C;C,T,G;G	317;319,1,1;321	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3558	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2315	191.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	824	824	C	247	C	247	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	46;49;52	T;T;A	46;49;52	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	94;94;94	C;A;T	94;94;94	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	94;94;94	A;G;T	94;94;94	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	94;94;94	T;A;C	94;94;94	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	3;3;3	T;C;G	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	3;3;3	A;G;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	226	90.27	porB1a.l15.c30.ctg.2	312	42.8	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	98	93.88	porB1a.l15.c30.ctg.3	178	59.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	132	134	ACG	71;66;63	A;C;G	71;66;63	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	392	porB1a	984	98	93.88	porB1a.l15.c30.ctg.3	178	59.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	174	176	CAA	17;16;12	C;A;A	17;16;12	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	747	749	GAA	339;338;335	G,T;A;A,G	338,1;338;334,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	1035	1037	GAT	332;332;335	G;A,G;T	332;330,2;335	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1158	1160	TCA	397;395;396	T;C,A;A,G	397;394,1;395,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1287	1289	GTC	340;341;339	G,A;T,A;C	338,2;340,1;339	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1299	1301	TCT	339;338;341	T;C,T;T	339;336,2;341	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1617	1619	GCA	334;337;339	G,T;C,A;A	333,1;336,1;339	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	1	SNP	p	G120K	1	.	.	358	360	AAG	993	995	AAG	357;358;359	A;A;G	357;358;359	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	1	SNP	p	A121D	1	.	.	361	363	GAC	996	998	GAC	359;362;362	G;A;C,G	359;362;361,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	4204	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	2054	254.5	1	SNP	p	D121N	0	.	.	361	363	GAC	996	998	GAC	359;362;362	G;A;C,G	359;362;361,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	14296	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5286	337.4	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2140	2142	AAT	352;347;351	A;A;T	352;347;351	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	2130	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1419	186.5	1	SNP	p	V57M	1	.	.	169	171	ATG	709	711	ATG	365;362;364	A;T,C;G	365;360,2;364	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
